ACTIVITY OVERVIEW | This Webcast contains video and downloadable slides from the symposium, Targeting Breast Cancer Molecular Phenotypes: A Dialogue Between Community and Academic Oncologists, a prIME Oncology educational activity that was held on 8 December 2011 during the 2011 Annual Breast Cancer Meeting in San Antonio. |
FACULTY | Chair
Kathy D. Miller, MD
Indiana University School of Medicine
Indianapolis, Indiana
Academic Faculty
Lisa Carey, MD
University of North Carolina
Chapel Hill, North Carolina
Stefan Glück, MD, PhD
University of Miami
Miami, Florida
Kelly Marcom, MD
Duke University Medical Center
Durham, North Carolina
Hope S. Rugo, MD
University of California San Francisco
San Francisco, California
Community Faculty
Linda Bosserman, MD
Wilshire Oncology Medical Group
Rancho Cucamonga, California
Kristina Bowen, MD
Georgia Cancer Specialists
Atlanta, Georgia
Lee Schwartzberg, MD
The West Clinic
Memphis, Tennessee
Steven Vogl, MD
Bronx, New York |
TARGET AUDIENCE | This educational activity is specifically designed for medical and surgical oncologists, radiologists, and other healthcare providers interested and/or involved in the treatment of patients with breast cancer. |
|
|
 |
|
Expert Discussion
|
 |
|
Clinical Case
|
 |
|
Downloadable Slides
|
|
 |
TOPICS | Defining Breast Cancer Molecular Phenotypes
Kathy D. Miller, MD
Treatment of luminal A and B breast cancers: Early-stage disease
Patient Presentation: Kristina Bowen, MD
Management Discussion: Kelly Marcom, MD
Treatment of luminal A and B breast cancers: Metastatic disease
Patient Presentation: Lee Schwartzberg, MD
Management Discussion: Hope S. Rugo, MD
Treatment of HER2-enriched breast cancers
Patient Presentation: Linda Bosserman, MD
Management Discussion: Stefan Glück, MD, PhD
Treatment of basal-like breast cancers
Patient Presentation: Steven Vogl, MD
Management Discussion: Lisa Carey, MD
|
LEARNING OBJECTIVES | After successful completion of this educational activity, participants should be able to:
- Discuss breast cancer tumor biology, how to identify breast cancer subtypes, and the importance of consideration of breast-cancer subtypes in treatment decision-making
- Identify the treatment options for patients with luminal cancer, including endocrine therapy, chemotherapy, novel targeted agents, and the role of gene expression assays in treatment decisions
- Describe current standards of care and recent clinical trial data on novel agents for HER2-enriched breast cancers, including therapeutic strategies to overcome resistance to standard therapies
- Compare and contrast recent clinical trial data on therapies for basal-like breast cancers, including novel chemotherapeutic and targeted strategies
|
Disclosures | Disclosure of Conflicts of Interest
prIME Oncology assesses conflicts of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of activities. All relevant conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.
Disclosure of Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
|
|
|
|
Sponsorship | This Webcast is a prIME Oncology activity.
|
|
